Prostate cancer is the second most common cancer in men, with a high mortality rate

While androgen deprivation therapy has improved the survival of patients with prostate cancer, treatment resistance inevitably leads to a castration-resistant stage, with subsequent metastasis

For patients with metastatic disease, treatment options are limited, and there is a lack of consensus in national treatment guidelines

This study examined the differing guidelines alongside data from a point-in-time survey of men with metastatic castration-resistant prostate cancer in five European countries and Japan

We found a general adherence to national treatment guidelines, but, with the introduction of new, more effective treatments, there is need for constant updates of international guidelines on the optimal treatment of advanced prostate cancer.